PNPavel Nagorny

Pavel Nagorny

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pavel Nagorny has a total of 208 co-authors. Here are the top co-authors by number of shared publications:

  • Oleksii Zhelavskyi

    Chemistry Department, University of Michigan, 930 N. University Ave. Ann Arbor, MI, USA, 48109

    8 shared publications
  • Paul Martin Zimmerman

    University of Michigan–Ann Arbor

    8 shared publications
  • Zhankui Sun

    Department of Chemistry, University of Michigan , 930 North University Avenue, Ann Arbor, Michigan 48109, United States

    7 shared publications
  • Paul M. Zimmerman

    Chemistry Department, University of Michigan, 930 N. University Ave. Ann Arbor, MI, USA, 48109

    6 shared publications
  • Sibin Wang

    Chemistry Department, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan 48109, United States

    6 shared publications
  • Alina Borovika

    Bristol-Myers-Squibb Co. 1 Squibb Dr. New Brunswick, NJ 08901, USA

    5 shared publications

Latest Publications

  • Open Access

    Asymmetric Immobilized Chiral Phosphoric Acid-Catalyzed Transfer Hydrogenation of Imines via Reductant Fine-tuning in Continuous Flow

    by Yin-Jia Jhang, Alex Chacko, Oleksii Zhelavskyi, Sejeong Park, Paul M. Zimmerman, Pavel Nagorny

    This article describes asymmetric transfer hydrogenation of imines with benzothiazolines using a chiral phosphoric acid (CPA) catalyst immobilized on a polystyrene support. We demonstrate that the reduction of imines with immobilized Ad-TRIP CPA using 2-napthyl-substituted benzothiazoline proceeds with excellent enantioselectivities to provide 15 chiral benzylic amines in 77-99% ee. By carrying the benzothiazoline reductant optimization in continuous flow, we were able to streamline the optimization process and identify a new superior benzothiazoline reducing agent featuring 3,5-di-tert-butylphenyl substituent that facilitated the reductions with significantly higher levels of enantiocontrol (up to 99% ee). To demonstrate the scalability of this process, a 1.1 gram-scale reduction with 3,5-di-tert-butylphenyl substituted benzothiazoline was achieved in continuous flow in 99% ee and 92% yield. In addition, a computational study using the double-ended growing-string method (GSM) and DFT established a stereochemical model for this reduction. Analysis of the hydride-transfer transition states leading to the major and minor enantiomers reveals that the selectivity arises from the interplay between a stabilizing π–π interaction with the catalyst that favors the major pathway and steric repulsions with the catalyst's 3,3′-substituents that disfavor the minor one.

  • Synthesis of Bufadienolide Natural Products and Analogs via Singlet Oxygen Oxidation and Late-Stage Modification

    by Colin Tichvon, Nasma Ibrahim, Kevin Kong, Pavel Nagorny

    In this work, we describe the synthesis of three new bufadienolide natural products cinobufotalin, bufotalin, and 5β-hydroxybufotalin and four new analogs of resibufogenin, bufalin, telocinobufagin, and marinobufogenin. This was achieved by developing a unified pathway that features installation of the characteristic α-pyrone ring onto steroid scaffolds with or without C5 oxygenation, and introduction of D-ring oxidation through a photochemical singlet oxygen [4 + 2] cycloaddition/endoperoxide rearrangement to furnish 14β,16β-bis-epoxides. Following a regioselective scandium(III) trifluoromethanesulfonate-catalyzed House-Meinwald rearrangement previously used to synthesize cinobufagin, these intermediates were elaborated to, cinobufotalin (13 steps LLS, 8.0% yield), bufotalin (12 steps LLS, 5.9% yield), and 5β-hydroxybufotalin (14 steps, 1.3% yield). This strategy was further extended to access new analogs of resibufogenin (26), bufalin (25), telocinobufagin (30), and marinobufogenin (29). Altogether, these studies describe the development of a general platform for accessing natural and unnatural bufadienolides from readily available androstenedione 5.

  • Open Access

    Total Syntheses of Bufadienolide Natural Products and Analogs via Singlet Oxygen Oxidation and Late-Stage Modification

    by Colin Tichvon, Nasma Ibrahim, Kevin Kong, Pavel Nagorny

    In this work, we describe a general approach that led to the synthesis of three natural steroids of bufadienolide family and four unnatural analogs. Building on our previous work, this unified pathway features installation of the characteristic α-pyrone ring to steroid scaffolds with or without C5 oxidation and introduction of D-ring oxidation through a photochemical singlet oxygen [4 + 2] cycloaddition to furnish two different 14β,16β-bis-epoxides. Following a regioselective House-Meinwald rearrangement, these intermediates could be elaborated to bufotalin (13 steps LLS, 5.0% yield), cinobufotalin (13 steps LLS, 17.5% yield), and 5β-hydroxybufotalin (14 steps, 11.9% yield). We also synthesized analogs 30, 31, 35, and 36 through late-stage modifications that enable more bufadienolide analogs to be generated and tested for biological activity.


  • Open Access

    Bioinspired Synthesis of Twin abeo ‐Steroids Bufogargarizins A and B via a Divergent Intramolecular Aldol Addition Reaction

    by Zoey J. Surma, Volodymyr Hiiuk, Eugene Zviagin, Yaxin Ouyang, Alex Chacko, Fengrui Qu, Paul M. Zimmerman, Pavel Nagorny

    This manuscript describes a concise bioinspired synthesis of twin abeo ‐steroids bufogargarizins A and B with an unusual [7.5.6.5] and [5.7.6.5] skeletons and a highly oxidized D‐ring with an α‐pyrone substituent from (+)‐methyl estrone. The described synthetic approach features ozonolytic cleavage of the Δ 5,10 ‐alkene of an easily available estrone derivative, followed by a bioinspired regio‐ and stereoselective intramolecular aldol addition reaction that produced the desired bufogargarizins A and B precursors with the [7.5.6.5] and [5.7.6.5] skeletons in 27% and 63% yields, correspondingly. This work provides direct evidence that proves the biosynthetic hypothesis for the first time, as prior synthetic studies suggest that only bufogargarizin B could be formed via an intramolecular aldol reaction. The subsequent installation of the β17‐pyrone moiety along with the β14, β15‐epoxide and β16‐acetoxy group was found to be challenging due to the instability of the α‐pyrone moiety to a range of basic, reductive, and oxidative conditions. To address this challenge, we have developed a singlet oxygen‐based oxidation method that results in a streamlined installation of the D‐ring oxidation and stereochemistry from a Δ 14,16 ‐diene precursor. This enabled the completion of the syntheses of bufogargarizins A and B in 19 steps (LLS) and 0.36 and 1.5% overall yields, respectively.


  • Open Access

    Bioinspired Synthesis of Twin abeo ‐Steroids Bufogargarizins A and B via a Divergent Intramolecular Aldol Addition Reaction

    by Zoey J. Surma, Volodymyr Hiiuk, Eugene Zviagin, Yaxin Ouyang, Alex Chacko, Fengrui Qu, Paul M. Zimmerman, Pavel Nagorny

    This manuscript describes a concise bioinspired synthesis of twin abeo ‐steroids bufogargarizins A and B with an unusual [7.5.6.5] and [5.7.6.5] skeletons and a highly oxidized D‐ring with an α‐pyrone substituent from (+)‐methyl estrone. The described synthetic approach features ozonolytic cleavage of the Δ 5,10 ‐alkene of an easily available estrone derivative, followed by a bioinspired regio‐ and stereoselective intramolecular aldol addition reaction that produced the desired bufogargarizins A and B precursors with the [7.5.6.5] and [5.7.6.5] skeletons in 27% and 63% yields, correspondingly. This work provides direct evidence that proves the biosynthetic hypothesis for the first time, as prior synthetic studies suggest that only bufogargarizin B could be formed via an intramolecular aldol reaction. The subsequent installation of the β17‐pyrone moiety along with the β14, β15‐epoxide and β16‐acetoxy group was found to be challenging due to the instability of the α‐pyrone moiety to a range of basic, reductive, and oxidative conditions. To address this challenge, we have developed a singlet oxygen‐based oxidation method that results in a streamlined installation of the D‐ring oxidation and stereochemistry from a Δ 14,16 ‐diene precursor. This enabled the completion of the syntheses of bufogargarizins A and B in 19 steps (LLS) and 0.36 and 1.5% overall yields, respectively.


  • Open Access

    Development of CPA‐Catalyzed β‐Selective Reductive Amination of Cardenolides for the Synthesis and Biological Evaluation of Hydrolytically Stable Analogs

    by Natasha Perry, Shehab Eid, Gerold Schmitt‐Ulms, Pavel Nagorny

    This article describes the development of novel, hydrolytically stable cardiotonic steroid analogs featuring a 3β‐amine moiety instead of the commonly found 3β‐carbohydrates such as oleandrose. To establish the desired 3β‐configuration stereoselectively, a new method based on chiral phosphoric acid‐controlled diastereoselective reductive amination with Hantzsch esters was developed. This method utilizes readily available unsubstituted (S)‐BINOL‐based hydrogen phosphate as the catalyst, enabling the synthesis of 13 different 5β‐androsterone and digitoxigenin analogs with up to 36:1 β:α diastereoselectivity. Additionally, this strategy was applied to generate two novel oleandrigenin analogs 15a and 15g in 3 steps from readily available gitoxigenin. The synthetic analogs were subjected to the NCI‐60 human tumor cell lines screen, and several different digitoxigenin derivatives with tumor cell growth inhibitory power in submicromolar range were identified. The subsequent in vitro evaluation of digitoxigenin and oleandrin derivatives 13a, 13g, 15a, and 15g demonstrated that these four analogs reduced steady‐state ATP1A1 levels in T98G cells in the 12–96 nM range. Interestingly, only the oleandrin analog 15g lowered also steady‐state levels of the cellular prion protein (PrPC), the main therapeutic target for the treatment of prion diseases.


  • Open Access

    Development of CPA-Catalyzed b-Selective Reductive Amination of Cardenolides for the Synthesis of Hydrolytically Stable Analogs

    by Natasha Perry, Gerold Schmitt-Ulms, Pavel Nagorny

    This article describes the development of novel, hydrolysis-resistant cardiotonic steroid analogs featuring a 3b-aniline moiety instead of the commonly found 3b-carbohydrates such as oleandrose. To establish the desired 3b-amine configuration stereoselectively, a new method based on chiral phosphoric acid-controlled diastereoselective reductive amination with Hantzsch esters was developed. This method utilizes readily available unsubstituted (S)-BINOL-based hydrogen phosphate as the catalyst, enabling the synthesis of 13 distinct 5b-androsterone and digitoxigenin analogs with up to 36:1 b:a diastereoselectivity. Additionally, this strategy was applied to generate a novel oleandrigenin analog 15 in three steps from the readily available gitoxigenin. The synthetic analogs were screened against the NCI-60 human tumor cell lines, revealing several digitoxigenin derivatives with potent tumor cell growth inhibitory activity and cytotoxicity in the submicromolar range.

  • Open Access

    Stereoelectronic Effect of Protecting Groups on the Stability of Galactosyl Donor Intermediates

    by Ryan W. Kwok, Ryan Rutkoski, Pavel Nagorny, Mateusz Marianski

    Using methods of DFT, we investigated the effect of electron withdrawing and electron donating groups on the relative stability of tentative glycosyl donor reaction intermediates. The calculation shows that by changing the stereoelectronic properties of the protecting group, we can influence the stability of the dioxolenium type of intermediates by up to 10 kcal mol−1, and that by increasing nucleophillicity of the 4-O-Bz group, the dioxolenium intermediate becomes more stable than a triflate–donor pair. We exploited this mechanism to design galactosyl donors with custom protecting groups on O2 and O4, and investigated the outcome of the reaction with cyclohexanol. The reaction showed no change in the product distribution, which suggests that the neighboring group participation takes precedence over remote group participation due to kinetic barriers.


  • Open Access

    Update on a brain-penetrant cardiac glycoside that can lower cellular prion protein levels in human and guinea pig paradigms

    by Shehab Eid, Wenda Zhao, Declan Williams, Zahra Nasser, Jennifer Griffin, Pavel Nagorny, Gerold Schmitt-Ulms

    Lowering the levels of the cellular prion protein (PrPC) is widely considered a promising strategy for the treatment of prion diseases. Building on work that established immediate spatial proximity of PrPC and Na+, K+-ATPases (NKAs) in the brain, we recently showed that PrPC levels can be reduced by targeting NKAs with their natural cardiac glycoside (CG) inhibitors. We then introduced C4’-dehydro-oleandrin as a CG with improved pharmacological properties for this indication, showing that it reduced PrPC levels by 84% in immortalized human cells that had been differentiated to acquire neural or astrocytic characteristics. Here we report that our lead compound caused cell surface PrPC levels to drop also in other human cell models, even when the analyses of whole cell lysates suggested otherwise. Because mice are refractory to CGs, we explored guinea pigs as an alternative rodent model for the preclinical evaluation of C4’-dehydro-oleandrin. We found that guinea pig cell lines, primary cells, and brain slices were responsive to our lead compound, albeit it at 30-fold higher concentrations than human cells. Of potential significance for other PrPC lowering approaches, we observed that cells attempted to compensate for the loss of cell surface PrPC levels by increasing the expression of the prion gene, requiring daily administration of C4’-dehydro-oleandrin for a sustained PrPC lowering effect. Regrettably, when administered systemically in vivo, the levels of C4’-dehydro-oleandrin that reached the guinea pig brain remained insufficient for the PrPC lowering effect to manifest. A more suitable preclinical model is still needed to determine if C4’-dehydro-oleandrin can offer a cost-effective complementary strategy for pushing PrPC levels below a threshold required for long-term prion disease survival.


  • Nanodisc Reconstitution and Characterization of Amyloid-β Precursor Protein C99

    by Bankala Krishnarjuna, Gaurav Sharma, Volodymyr M. Hiiuk, Jochem Struppe, Pavel Nagorny, Magdalena I. Ivanova, Ayyalusamy Ramamoorthy

    Amyloid precursor protein (APP) plays a pivotal role in the pathology of Alzheimer's disease (AD). Since the fragmentation of the membrane-bound APP that results in the production of amyloid-β peptides is the starting point for amyloid toxicity in AD, it is important to investigate the structure and dynamics of APP in a near-native lipid-bilayer environment. However, the reconstitution of APP into a stable and suitable membrane-mimicking lipid environment is a challenging task. In this study, the 99-residue C-terminal domain of APP is successfully reconstituted into polymer nanodiscs and characterized using size-exclusion chromatography, mass spectrometry, solution NMR, and magic-angle spinning solid-state NMR. In addition, the feasibility of using lipid-solubilizing polymers for isolating and characterizing APP in the native Escherichia. coli membrane environment is demonstrated.